Viruses from the diverse family of Paramyxoviridae include important pathogens and are applied in gene therapy and for cancer treatment. The Tupaia paramyxovirus (TPMV), isolated from the kidney of a tree shrew, does not infect human cells and neutralizing antibodies against other Paramyxoviridae do not cross-react with TPMV. Here, we present a vector system for de novo generation of infectious TPMV that allows for insertion of additional genes as well as targeting using antibody single-chain variable fragments. We show that the recombinant TPMV specifically infect cells expressing the targeted receptor and replicate in human cells. This vector system provides a valuable tool for both basic research and therapeutic applications.
INTRODUCTION
Specific targeting of distinct cell populations remains a key challenge in gene therapy and cancer treatment. Viral vectors from the family of Paramyxoviridae, especially those derived from measles virus (MeV) and Newcastle disease virus, have been used for gene delivery and treatment of cancer in preclinical and clinical trials [1] . Moreover, this virus family includes important human and animal pathogens such as mumps virus, MeV, respiratory syncytial virus, Nipah virus as well as canine distemper virus (CDV) and rinderpest virus [2] . The Tupaia paramyxovirus (TPMV) was originally isolated from degenerating kidney cells of an apparently healthy tree shrew (Tupaia belangeri) captured near Bangkok [3] . TPMV tropism is restricted to Tupaia cells and no serological cross-reactivity with other Paramyxoviridae was detected [3] . The TPMV glycoproteins hemagglutinin and fusion have been characterized extensively, revealing that receptor binding, not fusion protein processing, limits TPMV entry into other mammalian cells [4] .
Lack of an entry receptor has so far precluded the investigation of TPMV replication in human cells. Virus chimeras of TPMV and MeV with hybrid glycoproteins have been developed [5] . Despite the retained fusion capacity of the hybrid glycoproteins and successful rescue of viral particles from cDNA, replication of the chimeric viruses was severely impaired [5] .
Several strategies have been developed to redirect the tropism of Paramyxoviridae and target the viruses to selected cell surface antigens. One strategy exploits receptor-ligand interactions, as demonstrated for MeV with a hemagglutinin protein fused either to epidermal growth factor or insulin-like growth factor, allowing entry into cells expressing the respective receptors [6] . Another possibility is to fuse designed ankyrin repeat proteins to the viral attachment protein [7] . The most widely adopted approach uses antibody single-chain variable fragments (scFv) as specificity domains [8] . scFv have been applied to target TPMV hemagglutinin to carcinoembryonic antigen [4] and to CD20 in TPMV-pseudotyped lentiviral vectors [9] . The STAR (sixhis tagging and retargeting) system allows propagation of scFv-targeted viruses via an anti-His pseudoreceptor, without the necessity of receptor expression on the cell line used for propagation [10] .
Although the complete TPMV genome sequence is available (GenBank AF079780), a reverse genetics system for TPMV has not been described to date. In previous studies, TPMV was propagated on and recovered from infected Tupaia cells [3, 4] . A vector system that allows for genetic manipulation is a prerequisite for development of therapeutic approaches using recombinant viruses. Furthermore, a reverse genetics system for de novo generation of replication-competent viruses facilitates molecular characterization of a given pathogen. The diverse family of Paramyxoviridae has recently come into focus due to emerging zoonoses [11, 12] , warranting further studies of these viruses.
We have developed a vector system for the generation of recombinant TPMV which allows for targeting via scFv fragments and insertion of additional transgenes. We demonstrate de novo generation of infectious viruses from cloned cDNA and efficient production of recombinant viruses. The targeted viruses specifically transduce cells expressing the corresponding target receptor and replicate in primate and human cells. This TPMV vector system is a valuable tool both in research and therapeutic applications.
RESULTS
A versatile vector system for TPMV To generate a vector system for TPMV, the TPMV antigenomic cDNA was placed under control of the minimal cytomegalovirus (CMV)-derived promoter, leading to a viral antigenomic (+)RNA strand after transcription mediated by RNA polymerase II (RNA pol II) of the host cell. A hepatitis delta ribozyme sequence and polyA signal were inserted downstream of the TPMV trailer (tr) to ensure correct processing of the viral RNA genome to full-length at a multiple of six nucleotides. The vector contains an additional transcription unit consisting of a TPMV gene start signal, cloning site and TPMV gene stop signal. A sequence encoding enhanced green fluorescent protein (EGFP) as a reporter protein was inserted in this transcription unit (Fig. 1a) . For targeting of TPMV, a vector backbone was designed for insertion of antibody scFv. This vector, pcTPMV P-EGFP H-His 6 , also encodes a six-histidine tag (His 6 ) to allow propagation of targeted TPMV variants on Vero-aHis cells (Fig. 1b) [10] . TPMV targeted against CD20 and the epidermal growth factor receptor (EGFR) were obtained by inserting respective scFv into the SfiI and NotI restriction sites provided in TPMV P-EGFP H-His 6 (Fig. 1c) .
Rescue and propagation of recombinant TPMV Infectious TPMV were obtained by rescue from cloned cDNA in a protocol adapted from the MeV rescue system described previously [13, 14] . Tupaia baby fibroblasts (TBF) or Vero-aHis cells were transfected with expression plasmids for the TPMV polymerase complex and full-length antigenomic TPMV plasmids. Syncytia typically became visible 5-7 days after transfection of TBF (Fig. 2a) . Formation of small syncytia was also observed in Vero-aHis cells. Rescued TPMV were then passaged on TBF or Vero-aHis cells (Fig. 2b) . All combinations of cell lines for rescue and propagation were tested (Table 1) . Under the tested conditions the most efficient combination for generation of recombinant TPMV proved to be transfection of TBF for initial generation of infectious virus with subsequent passaging on Vero-aHis cells. Therefore, while TBF were used for routine rescue of recombinant TPMV, propagation was carried out on Vero-aHis cells. Interestingly, syncytia morphology differed between the two cell lines, with polymorphic punctate syncytia in TBF and oval syncytia with a bright green fluorescent rim in Vero-aHis.
With this optimized protocol, generation of TPMV particles was successful in approximately one out of three independent transfection experiments. Rescue efficiency, defined as successful recovery of replicating particles per transfection of 1Â10 5 cells, was slightly higher for TPMV P-EGPF HHis 6 (40 %) than for CD20-and EGFR-targeted variants (35 and 25 %, respectively). The complete genomes of all rescued TPMV constructs were sequenced after three to five passages. No mutations compared to the antigenomic cDNA constructs were observed.
Replication of targeted TPMV
After propagation of recombinant TPMV with a modified H protein on Vero-aHis cells, their titres were determined both on TBF and on Vero-aHis cells (Fig. 3) . After three to four passages, titres were in the range of 1-5Â10 5 on TBF and 1-6Â10 6 cell infectious units per millilitre (ciu ml À1 ) on Vero-aHis cells, respectively. Remarkably, titres determined on Vero-aHis were consistently about one log 10 higher than titres determined on the host cell line TBF (interaction term F=22.33, P=0.0003 by two-way ANOVA). Titre values of TPMV P-EGFP H-His 6 were between 2.5 and 4 times higher than titres of variants with scFv targeting. Titre values between the two targeted TPMV variants (HaCD20 and HaEGFR) within one cell line did not differ significantly (1.4 and 2.0Â10 5 on TBF, 1.2 and 1.6Â10 6 on Vero-aHis). Titre values of TPMV P-EGFP with an unmodified H protein were around 1.9Â10 5 ciu ml
À1
. On Vero-a His, this virus did not form any syncytia, yielding a titre below the detection limit of the assay (12.5 ciu ml
).
Viral entry and replication of the targeted virus TPMV P-EGFP HaCD20 were further assessed on TBF, Vero-aHis, Vero-CD20 and HT1080-CD20 cells, the latter two ectopically express the human B-lymphocyte antigen CD20. TBF represents a natural, permissive host cell line [3] . Vero is a type I IFN-deficient primate cell line which is routinely used for virus production. While CD20-targeted TPMV enters Vero-aHis cells via interaction of the His 6 tag and the anti-His pseudoreceptor, entry in Vero-CD20 cells is mediated via interaction of the CD20-specific scFv and the target cell antigen. HT1080 is a human fibrosarcoma cell line sensitive to both IFN and double-stranded RNA [15] . HT1080-CD20 cells stably express CD20. Thus, this panel of cell lines represents varying levels of susceptibility to TPMV both on the entry and post-entry level. Cell-type-specific titres of TPMV P-EGFP HaCD20 were determined on these cell lines (Fig. 4a) . The mean titre on TBF was 7.4Â10 5 ciu ml
. Titres on parental Vero and HT1080 cells neither expressing CD20 nor the anti-His pseudoreceptor were below the detection limit. Titres on Vero-aHis cells were almost one log 10 higher than on TBF, with a mean value of 4.2Â10 6 ciu ml
. On Vero-CD20 cells, the mean titre amounted to 1.4Â10 6 ciu ml
. The lowest mean titre was determined on HT1080-CD20 with 6.5Â10 4 , one log 10 lower than on TBF. These titres were used for inoculation of the cell lines at a cell-specific m.o.i. of 0.03 to monitor viral spread ( Fig. 4b ) and assess viral replication (Fig. 4c ). As controls, parental Vero and HT1080 cells were inoculated with TPMV using the same amount of virus as for Vero-aHis and HT1080-CD20, respectively. TBF formed small syncytia that rapidly spread across the entire cell layer. Parental Vero cellsneither expressing CD20 nor the anti-His pseudoreceptordid not show syncytia formation or EGFP expression. Infected Vero-aHis cells formed large round or oval syncytia with a bright fluorescent rim which began to burst approximately 24 h after inoculation. Initially, syncytia of Vero-CD20 cells were smaller, but developed to similar morphology as Vero-a His syncytia within 48 h after inoculation. HT1080-CD20 cells formed numerous syncytia of intermediate size and were lysed within 48 h after inoculation.
At 12 h intervals, infectious progeny were quantified to generate multi-step (m.o.i. of 0.03) growth curves (Fig. 4c) . Virus kinetics in TBF, Vero-aHis and HT1080-CD20 were similar, with a plateau in progeny particles at 48 h post infection (p.i.). In contrast, the number of progeny particles in Vero-CD20 cells continued to increase until 72 h p.i. This correlated with delayed viral spread in Vero-CD20 compared to Vero-aHis cells. As opposed to virus propagation, the highest maximum titres in multi-step growth curves were observed for TBF, followed by HT1080-CD20 cells.
Sfil Notl Vero-aHis cells produced less progeny particles. This was associated with earlier, pronounced lysis of Vero-aHis cells beginning between 36 and 48 h p.i.
Targeted transduction of human cell lines
To assess transduction specificity of targeted TPMV, human cell lines with varying levels of EGFR surface expression were inoculated with TPMV P-EGFP HaEGFR (Fig. 5 ). As controls, cells were also inoculated with TPMV targeted to CD20 and non-targeted TPMV displaying only the His 6 tag. These two TPMV variants did not transduce the EGFR-positive, CD20-negative cells lines, as exemplified for U87 glioblastoma cells in Fig. 5a . EGFR-targeted TPMV transduced all tested human EGFR-positive cell lines, although with varying efficiency (Fig. 5b) 
DISCUSSION
Here we report establishment of a vector system for the generation of recombinant TPMV which allows targeting to selected surface receptors as well as expression of additional genes in transduced cells. Expression of an antigenomic (+) RNA strand is mediated by a minimal CMV-derived RNA 
pol II promoter, which has previously been identified as an efficient method for de novo generation of Mononegavirales particles [14] . The vector system is designed to incorporate scFv of selected specificity which can easily be exchanged via provided restriction sites. Provided that a suitable scFv is available, targeted TPMV with the receptor tropism of choice can be generated.
In this study, we generated TPMV targeted to CD20 and EGFR, respectively. A His 6 tag displayed on the TPMV attachment protein H allows for propagation of recombinant TPMV on Vero-aHis cells. However, de novo generation of particles in Tupaia cells proved to be more efficient than in Vero-aHis cells. Despite cell fusion, passaging of infectious virus failed after transfection of Vero-aHis cells under the tested conditions. Additional optimization may be required to successfully rescue infectious TPMV in VeroaHis cells. In contrast, further virus propagation on Vero-a His yielded more progeny than on TBF. These findings could reflect the different requirements of initial viral assembly versus replication and spread of viral progeny. Sequencing of the complete genomes of all recombinant TPMV ruled out selection of virus variants with improved fitness after rescue in TBF. Remarkably, when virus stocks were titrated in parallel on TBF and Vero-aHis cells, titres in the primate cell line were almost 10 times higher than in the cell line derived from the natural host. In multi-step growth curves, the number of viral progeny recovered from Vero-aHis were lower. These findings could, in part, be explained by more efficient fusion via the His 6 -aHis pseudoreceptor interaction, since the titre of TPMV targeted to CD20 on Vero-CD20 cells amounted to only a third of the titre on Vero-aHis cells. Vero-aHis syncytia may have burst before the maximum of infectious particles were generated. Titres of targeted TPMV variants were only around three times lower than titres of the parental virus, showing that insertion of scFv fragments did not severely compromise viral assembly or replication capacity. Titres on HT1080-CD20, a human IFN-responsive cell line, were one log 10 lower than on TBF in parallel titration experiments and multi-step growth curves. Taken together, these results illustrate that cell origin, receptor usage and IFN sensitivity influence viral transduction and kinetics of targeted TPMV in different cell types.
Transduction of different human cells with varying levels of EGFR surface expression revealed that syncytia formation did not strictly correlate with receptor abundance. This demonstrates that aside from receptor binding and fusion, post-entry events determine viral protein expression and spread. EGFR-positive, CD20-negative cells were not transduced by TPMV P-EGFP HaCD20 or TPMV P-EGFP HHis 6 , confirming that scFv specificity, not the presence of any scFv moiety or the His 6 tag, determines the tropism of targeted TPMV.
TPMV naturally binds to an unknown receptor on Tupaia cells which is not expressed on human cells. This obviates the need for 'detargeting' of recombinant TPMV, as opposed to e.g. MeV, where mutation of the binding sites for the natural receptors is required to fully redirect virus tropism and residual binding to the natural receptors may impair specificity and cause off-target effects. Tupaia species, classified as a separate order (Scandentia), are closely related to primates and have therefore attracted attention as an animal model for viral infections and cancer [16, 17] . Different mechanisms to evade the IFN response and enable efficient replication in host cells have evolved in different Paramyxoviridae [18] and at least in part determine the host range [19, 20] . The targeted viruses in this study demonstrate that, aside from the missing receptor on human cells, TPMV can rather efficiently replicate in human cells. The evolutionary relationship between Tupaia and primates may facilitate TPMV replication in human cells.
Recent studies have found a variety of paramyxoviruses related to TPMV in bats and other animals [21, 22] , including rodents from geographical regions as diverse as Trinidad [23] and Australia [24] . Taking into account that Nipah and 3 . Titres of recombinant TPMV. TPMV P-EGFP H-His 6 , TPMV P-EGFP HaCD20 and TPMV P-EGFP HaEGFR were propagated on Vero-a His cells. After three (TPMV P-EGFP H-His 6 , TPMV P-EGFP HaCD20) or four (TPMV P-EGFP HaEGFR) passages, titres were determined on TBF and on Vero-aHis cells as ciu ml À1 . TPMV P-EGFP with unmodified H was propagated on TBF (two passages). Mean values of octuplicates are shown. Error bars indicate the standard error of the mean. The dotted line indicates the detection limit of the titration assay (12.5 ciu ml À1 ). The dark grey bar indicates a titre below the detection limit.
Hendra viruses were able to cross the species barrier and infect humans, it is reasonable to further pursue the detailed molecular characterization of these viruses. The TMPV reverse genetics system presented here will be a useful basis for this work.
Despite the phylogenetic relationship between TPMV and human pathogens, no serological cross-reactivity with other Paramyxoviridae has been observed [3] . The absence of TPMV-reactive antibodies in human subjects has spurred the development of TPMV-pseudotyped lentiviral vectors for gene therapy [9] . The high prevalence of antibodies especially against MeV could hamper efficacy of MeVderived therapeutics. To address this issue, chimeric viruses with CDV glycoproteins have been developed [25] . However, sequential therapy with several vectors may be required to enhance efficacy or as part of prime-boost regimens. To this end, TPMV-MeV chimera were developed previously, which only produced a minimal number of viral progeny [5] . The TPMV vectors presented here retain full replication potential and can therefore be considered a valuable addition to the repertoire of Paramyxovirus vectors.
In summary, we have established a versatile vector system for de novo generation of targeted TPMV from cloned antigenomic cDNA. Recombinant TPMV specifically transduce cells expressing the cognate receptor and replicate in human cells. The vector system presented here may prompt further studies of TPMV virology as well as evaluation of TPMVderived vectors for therapeutic applications.
METHODS Plasmids
To generate expression plasmids for TPMV N, P and L proteins, total RNA isolated from infected TBFs was reverse transcribed into cDNA and amplified by PCR using the primers (restriction sites used for cloning are underlined): TPMV-N-F (5¢-AAATTTGCGGCCGCATGGCAGATTTG TTCAGC-3¢); TPMV-N-R (5¢-AAATTTGCTAGCTCAAG GTGATTGATTGATG-3¢); TPMV-P-F (5¢-AAATTTGC GGCCGCATGAATAACACCGAGATCATTG-3¢); TPMV-P-R (5¢-AAATTTGCTAGCTCAATTTTTAAGATTCTTG ATAATG-3¢); TPMV-L-F (5¢-AAATTTGCGGCCGCTA TGGACAACCAGTTGGGCGACG-3¢); TPMV-L-R1 (5¢- 
GAACAGAAGAAATGGACAAC-
Expression plasmids for measles virus (MeV) N, P and L proteins driven by the CMV promoter, pCA-MV-N, pCA-MV-P and pCA-MV-L, were obtained from Urs Schneider (University of Freiburg, Germany). The MeV ORFs were replaced by the respective TPMV sequences via 5¢-NotI and 3¢-NheI restriction sites (N and P ORF). In the case of TPMV L, individual cDNA fragments were cloned into TOPO vectors. cDNA fragments were further amplified by PCR, joined by PCR ligation with flanking primers and inserted into pCA via NotI/XhoI. Constructs were verified by sequencing. Details about the cloning strategies are available upon request.
Plasmids harbouring a cDNA copy of the full-length TPMV genome were obtained from Andrew Hudacek (Mayo Clinic, Rochester, MN, USA). Numbered nucleotide positions are based on the GenBank accession number AF079780 and refer to the annotated antigenomic viral sequence. Plasmid pBR(+)TPMV contains the wild-type cDNA sequence under the control of the T7 promoter, leading to a viral antigenomic (+)RNA strand after transcription in a T7 expression system commonly used for the rescue of non-segmented negative-strand RNA viruses [26] . Plasmid p(+)TPMVdAleI (ECFP)M harbours an additional transcription cassette (ATU) between the P and M genes, encoding the reporter enhanced cyan fluorescent protein (ECFP).
In order to switch from the T7 RNA polymerase-based rescue system to the cellular RNA pol II-controlled system [14] , in essence, the T7 promoter and terminator elements were replaced by the minimal CMV promoter and a polyA signal sequence (derived from the Herpes simplex virus tk gene) downstream of the hepatitis delta virus (HDV) ribozyme sequence, respectively, resulting in the full-length pol II-controlled plasmid pcTPMV.
To obtain a pol II-controlled plasmid with TPMV encoding a reporter gene, first, the SanDI-NruI fragment (wild-type region from P to H gene) was exchanged for the SanDINruI fragment from p(+)TPMVdAleI (ECFP)M containing the ATU with ECFP downstream of the P gene, resulting in pcTPMV P-ECFP. Then, the ECFP ORF was replaced by a MluI-AscI fragment (732 bp) comprising the EGFP ORF in rule of six [27] , leading to pcTPMV P-EGFP.
The next step was to provide a universal genomic pcTPMV recipient plasmid that can accept any coding sequence of a specific single-chain antibody against a selected antigen and is fused to the C terminus of the H protein, ending with a histidine hexamer tag for subsequent rescue and propagation (STAR system; [10] ). First, the subgenomic SphI-SphI fragment (8092 bp) of pcTPMV P-EGFP comprising the region from the 3¢-end of the F gene to the 3¢-end of the L gene (positions 7091-15182) was cloned into pUC19, resulting in pUC-TPMV Sph-Sph. To obtain the modified scFvacceptor H ORF, two PCR fragments using long oligonucleotides were generated. In the subgenomic plasmid pUC-TPMV Sph-Sph, the BsrGI-BsrGI fragment (wild-type region from H position 8034 to L position 11831) was then exchanged for the BsrGI-NotI fragment (2150 bp) from PCR #1 and NotI-BsrGI from PCR #2 (1755 bp) in a three-way ligation protocol. The resulting plasmid pUC-TPMV H-SfiNotHis 6 was verified by restriction analysis and sequencing. Next, the SphI-SphI fragment (8200 bp) of this donor plasmid containing the modified scFv-acceptor H ORF was inserted back into the above SphI-SphI TPMV backbone (14 327 bp), resulting in the full-length genomic plasmid pcTPMV P-EGFP H-His 6 . Finally, the short (Serin-Glycin 4 ) 3 stuffer was excised via SfiI and NotI and replaced by the SfiI-NotI fragment harbouring the coding sequences for the scFv against EGFR or against CD20 isolated from expression plasmids of retargeted MeV H proteins pCG-HaEGFR [28] and pCG-HaCD20 [29] , resulting in the genomic constructs of targeted pcTPMV P-EGFP HaEGFR and pcTPMV P-EGFP HaCD20, respectively. The integrity of all constructs was verified by restriction digest and sequencing.
Sequences of TPMV antigenomic constructs were deposited in GenBank and are available under the following accession numbers: TPMV P-EGFP -MF379626; TPMV P-EGFP_H-His 6 -MF379627; TPMV P-EGFP_HaEGFR -MF379628; TPMV P-EGFP_HaCD20 -MF379629.
Cell culture TBFs have been described previously [30] . African green monkey kidney Vero cells, the human pancreatic adenocarcinoma cell line BxPC-3, SKOV3 ovarian adenocarcinoma, U87 glioblastoma and Raji lymphoma cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Vero-aHis cells, which stably express a membranebound single-chain antibody fragment specific for a His 6 tag, were a gift of S. Russell (Mayo Clinic, Rochester, MN, USA). Vero-CD20 cells were generated by lentiviral transduction as described previously [31] . The human fibrosarcoma cell line HT1080-CD20 was generated by stable transfection [32] . DLD-1 cells were provided by S. Fröhling (DKFZ Heidelberg, Germany). HNO97 cells derived from a lymph node metastasis of oral cavity cancer were provided by C. Herold-Mende (University Hospital Heidelberg, Germany). The mammary carcinoma cell line MCF-7 was a gift from D. Herr (University Hospital Ulm, Germany). TBF, Vero, Vero-aHis, Vero-CD20, U87 and HNO97 cells were cultivated in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Darmstadt, Germany) supplemented with 10 % (vol/vol) FBS (Biosera, Boussens, France). HT1080-CD20 were cultivated in DMEM with 10 % FBS and 3 µg ml À1 Puromycin (Life Technologies). BxPC-3, SKOV3, DLD-1, MCF-7 and Raji cells were cultivated in Roswell Park Memorial Institute medium (Life Technologies) supplemented with 10 % FBS. Cells were maintained in a humidified incubator at 37 C with 5 % CO 2 . All cell lines tested negative for mycoplasma contamination using the Venor GeM Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany).
Rescue of TPMV from cloned cDNA To generate TPMV from antigenomic cDNA, TBF were seeded in six-well plates (2Â10 5 cells per well). After 24 h, cells were transfected with 0.5 µg each of pCA-TMPV-N, -P and -L, 5 µg of the respective full-length pcTMPV plasmid as well as 0.1 µg pcDI-DsRed (to monitor transfection efficiency) using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. After 5 h of incubation, the transfection mixture was removed and replaced by 2 ml of fresh DMEM +10 % FBS and 50 µg ml À1 Kanamycin. When syncytia became visible, 5-10 days after transfection, cells were scraped in the culture medium and frozen at À80 C until further passaging.
Virus propagation and titration
Vero-aHis cells were used for propagation of TPMV. For passage #1, 2Â10 5 cells per well were seeded in six-well plates 24 h prior to passaging. Rescue samples were thawed, vortexed and cleared of cell debris by centrifugation (5 min, 5000 g, 4 C). The culture medium was removed and the Vero-aHis cells were inoculated with supernatants of rescue samples. After 6 h, the inoculum was replaced by 1 ml fresh culture medium (DMEM +10 % FBS). Viruses were harvested approximately 48 h after inoculation, when syncytia had formed but had not yet burst. For harvesting, cells were scraped in the culture medium, samples were vortexed and cell debris was removed by centrifugation (5 min, 5000 g, 4 C). Supernatants were stored at À80 C in aliquots for titration and further use.
To prepare virus stocks at larger scale, Vero-aHis cells were infected at an m.o.i. of 0.03 and incubated at 37
C for approximately 48 h. All following experiments were performed with virus stocks from the third, fourth or fifth passage.
TPMV titres were determined in octuplicates by 10-fold serial dilutions in 96-well plates with 1.5Â10 4 cells per well. After 48 h, syncytia were counted and titres were calculated as ciu ml À1 virus suspension in a variation of the plaque assay as described by Dulbecco and Vogt [33] .
Sequencing of TPMV genomes
The complete genomes of all viruses were sequenced after three to five passages on Vero-aHis cells. To this end, RNA was extracted from virus stocks using the QIAAmp viral RNA Mini kit (Qiagen, Hilden, Germany) and cDNA synthesis was performed using the Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Fisher, Schwerte, Germany). Sanger sequencing was performed by GATC Biotech (Konstanz, Germany). Primers used for sequencing are available upon request.
Growth curves
Cell-type-specific titres of TPMV P-EGFP HaCD20 were determined on TBF, Vero-aHis, Vero-CD20 and HT1080-CD20 cells. Mean values of three titration assays were used to calculate the amount of virus suspension for each cell line. For Vero cells, titres determined on Vero-aHis cells were used. Cells were seeded in 12-well plates (1Â10 5 cells per well) with triplicates for each time point. After 24 h, cells were inoculated with TPMV P-EGFP HaCD20 at an m.o.i. of 0.03 as described above. At designated time points, cells were scraped in the culture medium, triplicate samples were pooled, vortexed, cleared of cell debris by centrifugation (5 min, 5000 g, 4 C) and samples were frozen at À80 C. Progeny TPMV particles were determined by titration in quadruplicates on Vero-aHis cells.
Statistical analysis
Titration results were analysed by two-way ANOVA with Bonferroni correction for multiple comparison using GraphPad Prism software (Version 5.04, GraphPad Software).
Flow cytometry
To assess EGFR surface expression of U87, BxPC-3, DLD-1, SKOV3, HNO97, MCF-7 and Raji, 1Â10 5 cells were stained with a PE-labelled anti-human EGFR antibody (clone AY13; BioLegend, San Diego, CA, USA) at a concentration of 0.2 µg ml À1 in 100 µl PBS supplemented with 2 % FBS. PE-labelled mouse IgG1k (clone MOPC-21; BD Biosciences, Heidelberg, Germany) was used as an isotype control. Cells were additionally stained with DAPI (0.2 µg ml À1 ) for dead cell exclusion. Flow cytometry was performed on an LSR II Instrument (BD Biosciences) and data were analysed using FlowJo V10 software (Tree Star, La Jolla, CA, USA).
Targeted Infection TPMV titres were determined on Vero-aHis cells as described above. Cells from indicated cell lines were seeded in 12-well plates (1Â10 5 cells per well). Twentyfour hours later, cells were inoculated with 1.5Â10 5 ciu TPMV P-EGFP HaEGFR, corresponding to an m.o.i. of 1. Virus suspensions were diluted with OptiMEM (Life Technologies) in a total volume of 300 µl. After 3 h, the inoculum was removed and replaced by 1 ml of culture medium. Images were taken using a Zeiss Axiovert 200 fluorescence microscope (Carl Zeiss, Jena, Germany) and Axiovision 4.7 software (Carl Zeiss).
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